This article examines the potential of GLP-1 receptor agonists, commonly used for type 2 diabetes and obesity, in treating polyendocrine metabolic ovarian syndrome (PMOS). Experts discuss the benefits, who may benefit the most, and the limitations of this treatment option.
A study published in Science Advances reveals that the experimental drug TOFA enables obese mice to lose fat without reducing their food intake or losing muscle mass. The compound…
A recent study from Yale University has identified several interventions that may effectively slow the aging process. The research highlights the importance of prescribed medicati…
As obesity medications evolve, researchers are exploring new hormone combinations to enhance treatment effectiveness and tolerability. Current studies focus on therapies that not…
New research from Yale University has uncovered surprising effects of Ozempic, a GLP-1 medication, on hunger neurons in the brain. Contrary to previous beliefs that these neurons…
Recent discussions suggest that GLP-1 medications, primarily used for weight loss and diabetes management, may also lower the risk of developing dementia. However, while some obse…
Research indicates that GLP-1 drugs, typically used for obesity treatment, may also effectively address polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder affect…
Recent research has revealed that semaglutide, a popular weight-loss drug, may operate through mechanisms involving hunger neurons, challenging previous understandings of its effe…
As GLP-1 medications gain popularity among U.S. adults, health and fitness coaches are adapting their approaches to support clients using these drugs. This article explores seven…
The Health Products Regulatory Authority (HPRA) has confirmed over 1,500 reports of suspected adverse reactions related to anti-obesity medications, including serious gastrointest…
A recent clinical trial published in Nature Medicine reveals that aleniglipron, an oral GLP-1 medication, helped adults with obesity or overweight lose up to 12.1% of their body w…
A recent study from Yale University has uncovered a surprising mechanism by which GLP-1 therapies, like Ozempic, support sustained weight loss. Contrary to previous beliefs that t…
Yale researchers have revealed a new certification process for anti-aging treatments that mandates diet and prescription medications while deeming popular supplements ineffective,…
Novo Nordisk's stock fell by 7% after the company revealed its long-term growth strategy at a capital markets day, raising investor concerns about its ability to maintain its posi…